HomeMarket NewsLyra Therapeutics Exceeds EPS Expectations but Falls Short on Revenue in Q4...

Lyra Therapeutics Exceeds EPS Expectations but Falls Short on Revenue in Q4 2023

By Ron Finklestien
Current Market Analysis

Actionable Trade Ideas

always free

LYRA stock - LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023

Source: iQoncept / Shutterstock

Lyra Therapeutics (NASDAQ:LYRA) has recently revealed its performance figures for the fourth quarter of 2023.

  • Lyra Therapeutics posted earnings per share of -22 cents, surpassing the projected EPS of -31 cents by analysts.
  • The company’s revenue totaled $146,000, falling significantly short by 62.56% compared to the anticipated revenue of $390,000.

InvestorPlace Earnings initiative, powered by data from TradeSmith, serves to automatically cover quarterly earnings reports. This project distills crucial highlights like earnings per share, revenue, and the company’s alignment with analyst forecasts. The articles are disseminated without direct human input, ensuring expeditious delivery of the latest financial metrics to our readers. Should you encounter any concerns or discrepancies, please reach out to us at editor@investorplace.com.

Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/lyra-stock-earnings-lyra-therapeutics-for-q4-of-2023/.

©2024 InvestorPlace Media, LLC

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.

Read Now

Related Articles

spot_img

WallStreet Waves

Comprehensive stock market news coverage across various asset classes, including stocks, bonds, commodities, cryptocurrencies, and more. We believe in offering a holistic perspective, allowing our readers to stay ahead of the stock market and capitalize on emerging opportunities in tech stocks, small caps, biotechs and more!

most Popular

trending right now

© 2024 All Rights reserved | Powered by WallStreet Waves